IL1B and metabolic syndrome: Consistent unfolding of the intricate links between MetS, inflammation and pathogens may further point at novel therapeutic avenues; one recent example is anti-IL-1β antibodies investigated for secondary prevention of myocardial infarction (Ridker et al., 2017).